(-1.45%) 5 042.14 points
(-1.38%) 37 855 points
(-1.86%) 15 686 points
(-1.23%) $81.61
(-2.76%) $1.974
(-2.22%) $2 305.40
(-3.90%) $26.58
(-1.60%) $946.15
(0.48%) $0.937
(1.07%) $11.10
(0.54%) $0.800
(0.15%) $93.44
6.07% HKD 5.94
Live Chart Being Loaded With Signals
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States...
Stats | |
---|---|
Volumen de hoy | 2.01M |
Volumen promedio | 1.27M |
Capitalización de mercado | 3.42B |
EPS | HKD0 ( 2024-03-26 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -4.01 |
ATR14 | HKD0.0330 (0.57%) |
Volumen Correlación
CARsgen Therapeutics Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
CARsgen Therapeutics Correlación - Moneda/Commodity
CARsgen Therapeutics Finanzas
Annual | 2023 |
Ingresos: | HKD0 |
Beneficio Bruto: | HKD0 (0.00 %) |
EPS: | HKD-1.340 |
FY | 2023 |
Ingresos: | HKD0 |
Beneficio Bruto: | HKD0 (0.00 %) |
EPS: | HKD-1.340 |
FY | 2022 |
Ingresos: | HKD0 |
Beneficio Bruto: | HKD0 (0.00 %) |
EPS: | HKD-1.620 |
FY | 2021 |
Ingresos: | HKD25.81M |
Beneficio Bruto: | HKD25.81M (100.00 %) |
EPS: | HKD-8.36 |
Financial Reports:
No articles found.
CARsgen Therapeutics
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico